Anavex Life Sciences Corp. director Peter Donhauser reported the acquisition of 50,000 stock options on November 3, 2026, in a statement of changes in beneficial ownership filed with the SEC on November 6, 2026.

Key Highlights

  • Reporting person: Peter Donhauser, identified as a director of Anavex Life Sciences Corp. (NASDAQ:AVXL)
  • Transaction date: November 3, 2026, with the filing submitted on November 6, 2026
  • Options acquired: 50,000 stock options (right to buy) with an exercise price of $1.20 per share
  • Expiration date: November 2, 2036, giving the options a ten-year term
  • Vesting schedule: Options vest in three substantially equal annual installments beginning March 31, 2027
  • Post-transaction holdings: Donhauser beneficially owns 50,000 derivative securities following the reported transaction, held directly
  • Price paid: The filing reports $0 as the price of the derivative security at acquisition

Donhauser Stock Option Grant Details at Anavex Life Sciences

According to the filing, Peter Donhauser, a director of Anavex Life Sciences Corp., acquired 50,000 stock options on November 3, 2026, under transaction code "A" (acquired). The options carry an exercise price of $1.20 per share and are exercisable into common stock of the company. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol AVXL, focused on the development of treatments for neurodegenerative and neurodevelopmental diseases.

The filing discloses that the options are set to expire on November 2, 2036, representing a ten-year term from the transaction date. The price of the derivative security at the time of acquisition is listed as $0 in the filing. Donhauser's beneficial ownership of derivative securities following the transaction stands at 50,000, held directly. No non-derivative securities transactions were reported in Table I of the filing.

As noted in the filing's explanation of responses, "The option vests in three substantially equal annual installments beginning on March 31, 2027." The filing was signed by Peter Donhauser on November 6, 2026, and indicates this was filed by one reporting person. No amendment date was provided, indicating this is an original filing rather than a revision.

What Was Disclosed

Anavex Life Sciences Corp. director Peter Donhauser disclosed the acquisition of 50,000 stock options at an exercise price of $1.20, expiring November 2, 2036, vesting in three substantially equal annual installments beginning March 31, 2027, with $0 paid at grant.